What is Cartalax? (Bioregulator Mechanism Explained)

Most anti-aging compounds work by replacement. Adding back what the body has stopped producing. Cartalax operates on a fundamentally different model. It's a synthetic tripeptide bioregulator. A three-amino-acid sequence (Ala-Glu-Asp) designed to interact with specific DNA regions in aging cells, theoretically influencing gene expression rather than replacing missing hormones or enzymes. The mechanism isn't supplementation. It's genetic signaling.

Real Peptides has worked with research institutions studying peptide bioregulators since 2019. The gap between how these compounds are marketed online and what the peer-reviewed literature actually demonstrates is significant. That gap matters if you're designing a study protocol or evaluating research-grade sources.

What is Cartalax and how does it work in cellular research?

Cartalax is a synthetic tripeptide bioregulator composed of alanine, glutamic acid, and aspartic acid. Developed through Russian peptide bioregulator research, Cartalax is studied for its potential role in modulating gene expression in gastric tissue and other cells undergoing age-related decline. Unlike hormone replacement, Cartalax is theorized to bind to specific DNA sequences, potentially influencing transcription factors involved in cellular repair and protein synthesis.

The concept of bioregulators emerged from gerontology research conducted at the St. Petersburg Institute of Bioregulation and Gerontology under Professor Vladimir Khavinson. Cartalax belongs to a family of short peptides. Typically 2–4 amino acids. That researchers hypothesized could restore tissue-specific gene expression patterns that deteriorate with age. The work spans over 40 years, though Western adoption and independent replication remain limited.

Cartalax is classified as a research peptide, not an FDA-approved drug. Its mechanism involves hypothesized interaction with chromatin structures in the cell nucleus. The idea being that short peptides can penetrate cells, enter the nucleus, and bind near promoter regions of genes relevant to the tissue from which the original bioregulator sequence was derived. For Cartalax, that tissue is gastric mucosa. This article covers the amino-acid structure, proposed mechanism of action, existing research evidence, comparison to related bioregulators, practical research considerations, and the blunt reality of what current evidence does and does not support.

Cartalax Peptide Structure and Amino-Acid Composition

Cartalax is a tripeptide with the sequence Ala-Glu-Asp (alanine-glutamic acid-aspartic acid). Molecular weight is approximately 303 Da. The compound is synthesized. Not extracted from biological tissue. Which allows for precise amino-acid sequencing and eliminates contamination risk inherent in animal-derived peptide fractions. The tripeptide length is deliberate: sequences this short can theoretically cross cell membranes without requiring receptor-mediated endocytosis, the transport mechanism larger peptides depend on.

The specific amino-acid composition gives Cartalax its charge profile. Glutamic acid and aspartic acid are both acidic residues, contributing negative charge at physiological pH. This charge characteristic is thought to facilitate DNA binding, as the negatively charged peptide could interact with positively charged histone proteins or other chromatin-associated structures. Alanine, a small nonpolar residue, provides structural flexibility without introducing steric bulk that might prevent nuclear entry.

Cartalax is supplied as lyophilized powder, typically in 5mg or 10mg vials. Reconstitution requires bacteriostatic water. Standard protocol is 1–2ml per vial, producing a solution suitable for subcutaneous injection in research models. Stability post-reconstitution is approximately 28 days when stored at 2–8°C, consistent with most short-chain peptides. Unreconstituted Cartalax powder remains stable at −20°C for 24–36 months, provided the vial remains sealed and desiccated.

Real Peptides synthesizes Cartalax through solid-phase peptide synthesis (SPPS), the same method used for BPC-157 and Thymalin. Each batch undergoes HPLC verification to confirm amino-acid sequence accuracy and purity above 98%. The small-batch model ensures consistency. Relevant when a single substitution in a three-residue sequence fundamentally changes the peptide's identity. For labs running multi-month studies, batch-to-batch variability can confound results. We've worked with research groups that switched suppliers mid-study and saw outcome divergence not explained by the protocol. Sequencing verification traced it back to an alanine-to-glycine substitution in a claimed "Cartalax" product.

Proposed Mechanism of Action: Gene Expression and Cellular Bioregulation

The bioregulator hypothesis posits that age-related cellular decline results partly from altered gene expression. Not just damage accumulation or telomere shortening, but changes in which genes are transcribed and at what rate. Cartalax is theorized to restore tissue-specific gene expression patterns by binding to regulatory DNA sequences near genes involved in protein synthesis, cell cycle regulation, and repair pathways.

Here's how the proposed mechanism unfolds: Cartalax, administered subcutaneously, enters systemic circulation and crosses cell membranes. Its small size (three amino acids) allows passive diffusion or facilitated transport without requiring specific receptors. Once inside the cell, Cartalax enters the nucleus. Again, small peptides can traverse nuclear pores that exclude larger proteins. Inside the nucleus, Cartalax is hypothesized to bind to chromatin near promoter regions of genes relevant to gastric tissue function, potentially interacting with transcription factors or histone proteins.

This interaction theoretically modulates transcription. Either upregulating genes whose expression has declined with age or downregulating genes involved in inflammatory or apoptotic pathways. The tissue specificity is critical: Cartalax was derived from gastric mucosa peptide fractions in early bioregulator research. The hypothesis suggests that peptides retain "memory" of their tissue of origin, selectively influencing genes in that same tissue type even when synthesized rather than extracted.

The evidence base for this mechanism is preliminary. Russian studies published in journals like Advances in Gerontology and Bulletin of Experimental Biology and Medicine have shown changes in gastric cell proliferation markers, protein synthesis rates, and lifespan extension in animal models treated with Cartalax. A 2014 study by Khavinson et al. demonstrated increased expression of genes involved in protein synthesis and decreased expression of apoptosis-related genes in cultured human fibroblasts exposed to Cartalax. However, these findings have not been independently replicated in Western laboratories at scale.

One technical challenge: demonstrating that Cartalax. A tripeptide with no known receptor. Actually reaches the nucleus and binds to specific DNA sequences requires techniques like chromatin immunoprecipitation (ChIP) with peptide-specific antibodies. Published studies have used indirect markers (gene expression changes, proliferation assays) rather than direct binding evidence. That doesn't mean the mechanism is invalid. It means the molecular details remain less characterized than for receptor-based peptides like semaglutide or tirzepatide.

Cartalax vs. Other Peptide Bioregulators: Comparison Table

Peptide bioregulators form a family of compounds, each associated with a specific tissue. Understanding how Cartalax fits within this category requires comparing sequence, proposed target tissue, and research depth.

What If: Cartalax Research Scenarios

What If Cartalax Requires Chronic, Repeated Exposure to Show Measurable Effects?

Administer Cartalax daily or every other day for a minimum of 28 days in aging models before assessing gene expression or proliferation endpoints. Short-term studies (1–7 days) may miss cumulative transcriptional changes that require sustained peptide presence. Russian protocols typically use 10–20 day cycles repeated over months, suggesting bioregulator effects accumulate rather than manifest acutely. Design your study timeline accordingly. Single-exposure experiments may not capture the intended mechanism.

What If the Peptide Degrades Before Reaching Target Tissue?

Cartalax's tripeptide structure makes it vulnerable to peptidase cleavage in serum and tissue. Subcutaneous injection bypasses immediate hepatic first-pass metabolism, but circulating peptidases can still degrade Ala-Glu-Asp within minutes. If your model shows no effect, consider whether the peptide is reaching cells intact. Acetylated or amidated analogs (modifications that block peptidase cleavage) have been tested in related bioregulators. Verifying plasma stability via LC-MS at 15, 30, and 60 minutes post-injection can confirm whether degradation is limiting your results.

What If Cartalax Effects Are Tissue-Specific and Your Model Doesn't Reflect That?

Cartalax was derived from gastric mucosa and is hypothesized to selectively influence gastric tissue gene expression. If you're using non-gastric cell lines or tissues, the peptide may show minimal activity. Test Cartalax in gastric epithelial cells (e.g., AGS, MKN-45) or in vivo models with gastric aging phenotypes rather than generic fibroblast or muscle models. Tissue specificity is central to the bioregulator hypothesis. Using the wrong tissue type could yield false negatives.

The Research-Grade Truth About Cartalax

Here's the honest answer: Cartalax is one of the least-studied peptides in the bioregulator family outside Russian research institutions. The mechanism is theoretically compelling. Short peptides influencing gene expression at the chromatin level. But direct molecular evidence is sparse. You won't find Cartalax in PubMed with the same frequency as BPC-157 or Epithalon, and Western researchers have not replicated the gastric cell proliferation and lifespan studies at scale.

That doesn't mean Cartalax is ineffective. It means the evidence base is narrow, geographically concentrated, and mechanistically incomplete. If you're designing a study around gastric aging, age-related mucosal atrophy, or gene expression modulation in epithelial cells, Cartalax remains one of the few peptides specifically developed for that tissue target. The Russian literature shows consistent directional effects across multiple models. What's missing is the molecular detail: ChIP data showing DNA binding, concentration-response curves in human cells, and independent confirmation from labs outside the St. Petersburg Institute.

Real Peptides supplies research-grade Cartalax because labs request it for bioregulator studies. Not because the evidence base rivals more established peptides. If your research question aligns with tissue-specific gene modulation and you understand the evidence limitations, Cartalax offers a tool with a 40-year research lineage. If you're expecting the mechanistic clarity of a GLP-1 receptor agonist or the replication depth of NAD+ precursors, you'll be disappointed. The peptide is what it is: a Russian-developed bioregulator with compelling preliminary data and a long road to mechanistic validation.

For research applications involving gastric tissue aging, cellular bioregulation hypotheses, or comparative studies of short-chain bioregulators, Cartalax remains available in our full peptide collection. Every batch is verified by HPLC for sequence accuracy and stored under cold-chain conditions from synthesis to shipment. If you're running a multi-month aging study, consistency matters. One substituted amino acid and you're no longer testing Cartalax.

Cartalax won't be the answer if you need a peptide with established receptor targets, extensive pharmacokinetic data, or broad tissue effects. It will be relevant if your research question is: can a three-amino-acid sequence selectively influence gene expression in a specific tissue based on its peptide origin? That question remains open. And Cartalax is one of the few compounds designed explicitly to test it.

What Is Cartalax and Why Do Research Laboratories Study It?

Cartalax is a synthetic short peptide bioregulator, a tripeptide built from alanine, glutamic acid, and aspartic acid, that appears in the literature under the designation AED. It belongs to a family of ultrashort peptides developed on the premise that very small amino-acid sequences can interact with chromatin and influence transcription in specific tissue types. Within that family, Cartalax is associated with cartilage and connective-tissue research models, which is why it is frequently catalogued alongside other structural and repair-oriented compounds rather than with metabolic or appetite-focused sequences.

Laboratories purchase Cartalax as a lyophilized powder for in vitro work, cell-culture experiments, and animal model studies. It is supplied strictly as a reference compound and is not intended for human consumption. Buyers evaluating it typically arrive from the broader category of research peptides, where short sequences are compared on stability, synthesis difficulty, and analytical verifiability.

Interest in Cartalax usually overlaps with interest in anti-aging and longevity peptides and with the general question of how healing and recovery peptides work mechanistically. Researchers familiar with thymic fractions and what thymosins do often recognize the same Russian bioregulator research lineage behind Cartalax.

Who Developed Cartalax and What Is Its Research History?

Cartalax emerged from the Russian peptide bioregulator research program most closely associated with the St. Petersburg Institute of Bioregulation and Gerontology and the work of Vladimir Khavinson and colleagues. That program began with peptide fractions extracted from animal tissues — thymus, pineal, vascular, and cartilage preparations — and later moved toward synthetic di-, tri-, and tetrapeptides intended to reproduce the activity of the extracted fractions with defined, reproducible chemistry. Cartalax is the synthetic tripeptide counterpart within the cartilage-associated branch of that work.

The published output from this lineage spans several decades and includes cell-culture studies, rodent experiments, and reviews proposing that ultrashort peptides can enter cells, reach the nucleus, and interact with DNA sequence motifs. Much of this literature is published in Russian-language journals or in review form, which is why Western laboratories often treat the mechanistic claims as hypotheses requiring independent replication.

Researchers tracing this history commonly also examine best research practices for Thymalin, the thymic peptide preparation from the same program, and background on what creates thymosin. Cartalax is now routinely listed alongside other longevity-oriented peptides and evaluated using the same standards applied to any modern research peptide.

How Is Cartalax Purity Confirmed by HPLC and Mass Spectrometry?

Purity verification for Cartalax relies on two complementary analytical techniques. Reversed-phase high-performance liquid chromatography (RP-HPLC) separates the target tripeptide from truncated sequences, deletion products, residual coupling reagents, and scavenger byproducts left over from solid-phase synthesis. The chromatogram is integrated to report percentage purity, typically expressed as area percent at a defined ultraviolet wavelength. A clean single dominant peak with minimal shoulder features indicates a well-purified batch.

Mass spectrometry — usually ESI-MS or MALDI-TOF — confirms identity rather than purity. Because Cartalax is a tripeptide with a low molecular weight, the observed mass must match the calculated monoisotopic mass of the Ala-Glu-Asp sequence. Small peptides are particularly vulnerable to misidentification, since isomeric or near-isobaric impurities can co-elute, making the paired HPLC and MS report more meaningful than either alone.

Laboratories should expect both raw data files, not just a summary statement. Guidance on reading those files is covered in how to tell if a peptide supplier is legitimate, and the same analytical expectations apply across the wider research peptide market. Comparable documentation standards are discussed in best research practices for SNAP-8 and best research practices for TB-500.

What Should a Cartalax Certificate of Analysis Include?

A usable certificate of analysis (COA) for Cartalax should identify the compound by both name and sequence, state the batch or lot number, and give the date of manufacture and the date of analysis. The core data section needs an HPLC purity figure with the accompanying chromatogram, a mass spectrometry trace with calculated and observed mass, and the method parameters — column chemistry, gradient, mobile phase, and detection wavelength — so the result can be independently interpreted.

Beyond identity and purity, thorough COAs report appearance of the lyophilized solid, net peptide content versus gross weight (salt and residual water can account for a meaningful fraction of a vial's mass), and, where available, water content by Karl Fischer titration and residual solvent screening. Some suppliers add bacterial endotoxin or sterility data; these are optional for a research-use compound but useful for cell-culture work.

A COA issued by a third-party laboratory carries more weight than an in-house document with no analyst signature. The vetting framework in how to tell if a peptide supplier is legitimate applies directly, as do the documentation themes in research peptide legality and FDA rules and in best research practices for Adamax.

How Should Lyophilized Cartalax Be Stored in a Laboratory?

Lyophilized Cartalax is a dry, amorphous solid, and its stability depends mostly on keeping moisture, heat, and light away from it. Standard practice for short synthetic peptides is storage in a sealed, desiccated container at freezer temperatures, typically around −20 °C for routine use and colder for long-term archival stock. Sealed vials that have not been opened tolerate brief periods at refrigerated or ambient temperatures during shipping, which is why many suppliers transport small peptides without cold chain.

The main degradation risks for a sequence containing glutamic and aspartic acid residues are hydrolysis and aspartimide-related rearrangement, both accelerated by water and by extremes of pH. Allowing a cold vial to reach room temperature before breaking the seal reduces condensation on the powder. Repeated freeze-thaw cycling of stock material should be minimized, and vials should be kept away from direct light and from incompatible chemicals stored in the same freezer.

General compatibility considerations are summarized in what you should not mix peptides with. Storage logic for other light- and temperature-sensitive compounds is discussed in best research practices for melatonin and best research practices for Thymalin.

What Is the Regulatory Status of Cartalax for Research Buyers?

Cartalax has no approved human indication in the United States, the European Union, the United Kingdom, or Australia. It is not an FDA-approved drug, not a dietary supplement ingredient, and not a cosmetic ingredient with an established regulatory monograph. Lawful distribution is therefore limited to research-use-only (RUO) channels, with labeling that clearly states the material is not for human or veterinary consumption and not for diagnostic use.

Practically, this means Cartalax should be purchased by or on behalf of a laboratory, institution, or qualified researcher, stored as a laboratory chemical, and documented like any other reagent. Suppliers that market it with therapeutic claims, wellness framing, or consumer-style directions are operating outside the RUO boundary and create compliance exposure for the buyer as well as themselves.

Enforcement attention on peptide vendors has increased, and the category-level rules continue to shift; the current landscape is outlined in research peptides and FDA rules explained. Buyers should also understand the general legal framing that applies to all research peptides, and apply the supplier due-diligence checklist in how to tell if a peptide supplier is legitimate before placing any institutional order.

What Preclinical Models Are Used to Study Cartalax?

Published work on Cartalax and related ultrashort bioregulators has relied mainly on three experimental settings. The first is cell culture, where chondrocytes, fibroblasts, or organotypic tissue explants are exposed to the peptide and assessed for proliferation markers, protein synthesis, and expression of matrix-associated genes. The second is organ or tissue explant culture, a technique heavily used in the original Russian bioregulator program, which allows tissue architecture to be maintained while transcriptional responses are measured. The third is rodent models of aging or connective-tissue stress, where histological and biochemical endpoints are compared against untreated controls.

Common readouts include quantitative PCR or RNA sequencing for gene expression changes, immunohistochemistry for collagen and proteoglycan components, and viability or senescence assays. Because the proposed mechanism is transcriptional rather than receptor-mediated, binding assays that would be standard for a hormone analog are less informative here, and nuclear localization or DNA-interaction experiments are more relevant.

Researchers designing comparative studies often benchmark Cartalax against better-characterized structural compounds; see how healing and recovery peptides work, what BPC-157 and TB-500 do, and best research practices for TB-500 for established model designs.

Where Does Cartalax Fit Among Peptide Research Categories?

Peptide catalogues are usually organized by functional target, and Cartalax sits awkwardly across several of them. Because its proposed activity is transcriptional and tissue-selective rather than receptor-driven, it does not belong with secretagogues that act on defined G-protein-coupled receptors, nor with incretin analogs that engage metabolic signaling pathways. Its cartilage and connective-tissue association places it closest to structural and extracellular-matrix research compounds, while its origin in the bioregulator program places it within the gerontology literature.

The most useful framing for a laboratory is that Cartalax is a mechanistic probe. It is studied to test whether ultrashort peptides can produce measurable transcriptional effects in specific cell types, not to replicate the anabolic or metabolic endpoints associated with larger signaling peptides. That distinction matters when designing controls, since a bioregulator hypothesis demands gene-expression readouts rather than hormone assays.

For orientation across adjacent categories, see anti-aging and longevity peptides for the gerontology framing, skin anti-aging peptides for matrix and collagen-focused compounds, growth hormone secretagogue peptides for receptor-mediated contrast, and cognitive and nootropic peptides for other short sequences studied on transcriptional grounds.

How Can a Laboratory Vet a Cartalax Supplier Before Ordering?

Start with documentation. A supplier should provide a batch-specific COA with both an HPLC chromatogram and a mass spectrometry trace, not a generic PDF reused across lots. Cross-check the lot number on the vial label against the COA, and confirm that the stated sequence matches the Ala-Glu-Asp composition expected for Cartalax. If a vendor cannot produce raw analytical files on request, treat that as a material gap rather than an administrative inconvenience.

Next, examine how the compound is marketed. Research-use-only language should be consistent across the product page, packaging, and invoice. Therapeutic claims, wellness positioning, or consumer-facing instructions indicate a vendor operating outside RUO norms. Also review shipping and storage representations: a supplier that cannot explain how lyophilized material is handled in transit is unlikely to have robust internal controls.

Finally, assess operational signals — a verifiable business address, responsive technical support capable of answering analytical questions, and consistent lot-to-lot purity history. The full evaluation framework is set out in how to tell if a peptide supplier is legitimate, with the compliance backdrop in research peptides and FDA rules explained and category context in what research peptides are.